
## Jennifer C Nelson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12045119/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multiply Robust Causal Inference with Double-Negative Control Adjustment for Categorical Unmeasured Confounding. Journal of the Royal Statistical Society Series B: Statistical Methodology, 2020, 82, 521-540.	2.2	37
2	Leveraging the entire cohort in drug safety monitoring: part 1 methods for sequential surveillance that use regression adjustment or weighting to control confounding in a multisite, rare event, distributed data setting. Journal of Clinical Epidemiology, 2019, 112, 77-86.	5.0	3
3	Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multisite, rare-event, distributed setting: Part 2 in-depth example of a reanalysis of the measles-mumps-rubella-varicella combination vaccine and seizure risk. Journal of Clinical Epidemiology. 2019. 113. 114-122.	5.0	1
4	Challenges and Opportunities for Using Big Health Care Data to Advance Medical Science and Public Health. American Journal of Epidemiology, 2019, 188, 851-861.	3.4	39
5	Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics, 2019, 144, .	2.1	30
6	Sequential surveillance for drug safety in a regulatory environment. Pharmacoepidemiology and Drug Safety, 2018, 27, 707-712.	1.9	7
7	A Synthesis of Current Surveillance Planning Methods for the Sequential Monitoring of Drug and Vaccine Adverse Effects Using Electronic Health Care Data. EGEMS (Washington, DC), 2017, 4, 17.	2.0	8
8	Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. Pharmacoepidemiology and Drug Safety, 2016, 25, 973-981.	1.9	22
9	Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring. Statistics in Medicine, 2015, 34, 1117-1133.	1.6	4
10	Group sequential method for observational data by using generalized estimating equations: application to Vaccine Safety Datalink. Journal of the Royal Statistical Society Series C: Applied Statistics, 2015, 64, 319-338.	1.0	9
11	Safety of Measles-Containing Vaccines in 1-Year-Old Children. Pediatrics, 2015, 135, e321-e329.	2.1	38
12	Methods for observational post-licensure medical product safety surveillance. Statistical Methods in Medical Research, 2015, 24, 177-193.	1.5	15
13	Integrating database knowledge and epidemiological design to improve the implementation of data mining methods that evaluate vaccine safety in large healthcare databases. Statistical Analysis and Data Mining, 2014, 7, 337-351.	2.8	5
14	Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP–IPV) vaccine. Vaccine, 2014, 32, 3019-3024.	3.8	36
15	Timely Versus Delayed Early Childhood Vaccination and Seizures. Pediatrics, 2014, 133, e1492-e1499.	2.1	45
16	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. Pharmacoepidemiology and Drug Safety, 2014, 23, 1223-1225.	1.9	4
17	The test-negative design for estimating influenza vaccine effectiveness. Vaccine, 2013, 31, 2165-2168.	3.8	406
18	Vaccination Site and Risk of Local Reactions in Children 1 Through 6 Years of Age. Pediatrics, 2013, 131, 283-289	2,1	21

JENNIFER C NELSON

#	Article	IF	CITATIONS
19	Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV-Hib Vaccine Safety Study. American Journal of Epidemiology, 2013, 177, 131-141.	3.4	39
20	Further Evidence for Bias in Observational Studies of Influenza Vaccine Effectiveness: The 2009 Influenza A(H1N1) Pandemic. American Journal of Epidemiology, 2013, 178, 1327-1336.	3.4	37
21	Natural Language Processing to identify pneumonia from radiology reports. Pharmacoepidemiology and Drug Safety, 2013, 22, 834-841.	1.9	60
22	A Population-Based Cohort Study of Undervaccination in 8 Managed Care Organizations Across the United States. JAMA Pediatrics, 2013, 167, 274.	6.2	140
23	Angiotensinâ€converting enzyme inhibitor use and pneumonia risk in communityâ€dwelling older adults: results from a populationâ€based case–control study. Pharmacoepidemiology and Drug Safety, 2012, 21, 1173-1182.	1.9	13
24	Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini‣entinel pilot. Pharmacoepidemiology and Drug Safety, 2012, 21, 72-81.	1.9	43
25	Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiology and Drug Safety, 2012, 21, 62-71.	1.9	49
26	When should caseâ€only designs be used for safety monitoring of medical products?. Pharmacoepidemiology and Drug Safety, 2012, 21, 50-61.	1.9	123
27	A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiology and Drug Safety, 2012, 21, 282-290.	1.9	34
28	Use of Opioids or Benzodiazepines and Risk of Pneumonia in Older Adults: A Populationâ€Based Case–Control Study. Journal of the American Geriatrics Society, 2011, 59, 1899-1907.	2.6	155
29	A Propensity Score-Enhanced Sequential Analytic Method for Comparative Drug Safety Surveillance. Statistics in Biosciences, 2011, 3, 45-62.	1.2	4
30	Why do covariates defined by International Classification of Diseases codes fail to remove confounding in pharmacoepidemiologic studies among seniors?. Pharmacoepidemiology and Drug Safety, 2011, 20, 858-865.	1.9	10
31	Identifying optimal risk windows for selfâ€controlled case series studies of vaccine safety. Statistics in Medicine, 2011, 30, 742-752.	1.6	23
32	Injection Site and Risk of Medically Attended Local Reactions to Acellular Pertussis Vaccine. Pediatrics, 2011, 127, e581-e587.	2.1	24
33	Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiology and Drug Safety, 2010, 19, 792-802.	1.9	67
34	Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ: British Medical Journal, 2009, 338, b2137-b2137.	2.3	66
35	Risk Factors for Communityâ€Acquired Pneumonia in Immunocompetent Seniors. Journal of the American Geriatrics Society, 2009, 57, 882-888.	2.6	66
36	Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine, 2008, 26, 4947-4954.	3.8	144

JENNIFER C NELSON

#	Article	IF	CITATION
37	Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet, The, 2008, 372, 398-405.	13.7	159
38	To Rule Out Confounding, Observational Studies of Influenza Vaccine Need to Include Analyses During the "Preinfluenza Period― Archives of Internal Medicine, 2007, 167, 1553.	3.8	12
39	Induction of Labor in the Absence of Standard Medical Indications. Medical Care, 2007, 45, 505-512.	2.4	47
40	Evidence of bias in estimates of influenza vaccine effectiveness in seniors. International Journal of Epidemiology, 2006, 35, 337-344.	1.9	427
41	Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. International Journal of Epidemiology, 2006, 35, 345-352.	1.9	247
42	The reporting of pre-existing maternal medical conditions and complications of pregnancy on birth certificates and in hospital discharge data. American Journal of Obstetrics and Gynecology, 2005, 193, 125-134.	1.3	310
43	Accuracy of reporting maternal in-hospital diagnoses and intrapartum procedures in Washington State linked birth records. Paediatric and Perinatal Epidemiology, 2005, 19, 460-471.	1.7	183